Experts recommend osteoporosis patients continue Fosamax treatment

In recent years, evidence has emerged suggesting that patients who buy Fosamax and similar medications to treat osteoporosis may be more likely to experience fractures in certain bones. However, medical professionals are still insisting that these drugs are safe and should not be discontinued.

An advisory panel to the FDA recently recommended that the agency not restrict the availability of the medications, despite suggesting that updates to warning labels may be warranted.

Furthermore, the American Association of Clinical Endocrinologists recently released a statement saying that patients who currently buy Fosamax should continue to do so. Stopping treatment could result in potentially serious health hazards.

While a few studies have shown that individuals who take bisphophonates, the drug class to which Fosamax belongs, may be slightly more likely to experience fractured femurs, this evidence is not yet conclusive. Without these drugs, individuals with osteoporosis may experience a significant weakening of their bones.

For this reason, the association recommended that any decisions about using the drugs should be made on an individual basis in the counsel of a physician.